dihydroorotate dehydrogenase inhibitor
in Ph. I for RR-lymphoma
from opt. of literature molecule
Mol. Cancer Ther., Oct. 20, 2020
Agios Pharmaceuticals, Cambridge, MA
AG-636 (Agios Pharmaceuticals dihydroorotate dehydrogenase (DHODH) inhibitor clinical candidate)